MSFT
46
-7
F
48
-6
SWKS
37
5
TRIP
37
-7
HUM
36
-4
MLM
51
-3
NAVI
32
-4
AAL
20
-3
LUV
52
-4
HAS
53
5
INTC
36
-5
VRTX
49
-6
WFC
69
-5
CSX
36
-4
NWSA
71
-5
ICE
69
-5
UA
45
-2
WM
74
-2
EFX
58
-7
BA
39
-5
MSFT
46
-7
F
48
-6
SWKS
37
5
TRIP
37
-7
HUM
36
-4
MLM
51
-3
NAVI
32
-4
AAL
20
-3
LUV
52
-4
HAS
53
5
INTC
36
-5
VRTX
49
-6
WFC
69
-5
CSX
36
-4
NWSA
71
-5
ICE
69
-5
UA
45
-2
WM
74
-2
EFX
58
-7
BA
39
-5
Financhill
Back

CRISPR Therapeutics AG Stock Predictions

Apple's Drop in iPhone Sales Opens the Door for New Entrant

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
2

CRSP
CRISPR Therapeutics AG

Last Price:
$36.99
Seasonality Move:
19.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

CRISPR Therapeutics AG Stock Forecast

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 36.2% based on the past 8 years of stock performance.
  • CRISPR Therapeutics AG has risen higher in 4 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is CRISPR Therapeutics AG Stock Undervalued?
    The current CRISPR Therapeutics AG [CRSP] share price is $36.99. The Score for CRSP is 2, which is 96% below its historic median score of 50, and infers higher risk than normal.
  • CRSP is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.

Will CRISPR Therapeutics AG Stock Go Up Next Year?

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 36.2% based on the past 8 years of stock performance.

CRISPR Therapeutics AG Stock Rating

Sell
2
CRISPR Therapeutics AG (CRSP) is a Sell

Is CRISPR Therapeutics AG overpriced?

  • CRISPR Therapeutics AG has risen higher in 4 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

CRISPR Therapeutics AG Stock Price History

Is CRSP stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CRSP is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
crisprtx.com

52-Week Data

52-Week High:
70.12
52-Week Low:
36.52

Prediction Charts

Market Cap:
3.2B
Price in USD:
36.99
Volume:
1.6M
Beta:
2.00

Technical Analysis

SMA50:
42.66
SMA100:
44.53
SMA200:
47.96
52-Wk Change:
-45.73%

Stock Predictions

  • Is CRISPR Therapeutics AG stock public?
    Yes, CRISPR Therapeutics AG is a publicly traded company.
  • What is the CRISPR Therapeutics AG stock quote today?
    The CRISPR Therapeutics AG stock price is 36.99 USD today.
  • How to buy CRISPR Therapeutics AG stock online?
    You can buy CRISPR Therapeutics AG shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-11 42.93 42.37 43.34 40.82
Mar-12 42.64 43.49 43.94 42.42
Mar-13 43.20 41.99 44.39 41.63
Mar-14 42.55 42.12 43.48 41.94
Mar-17 41.94 42.82 43.32 41.46
Mar-18 42.67 40.97 42.67 40.40
Mar-19 41.20 41.94 42.75 40.70
Mar-20 41.23 41.17 42.50 41.03
Mar-21 40.71 41.22 41.68 40.41
Mar-24 42.00 42.62 42.72 41.88
Mar-25 42.50 40.89 42.50 40.78
Mar-26 40.80 39.18 40.88 39.14
Mar-27 39.00 38.04 39.28 37.85
Mar-28 37.99 36.99 38.20 36.93

CRISPR Therapeutics AG Earnings

CRISPR Therapeutics AG Earnings Report: Per Share CRISPR Therapeutics AG Earnings Q1 Q2 Q3 and Q4 last year and next year.

CRISPR Therapeutics AG Forecast Revenue Growth

CRISPR Therapeutics AG Stock Analysis: Historical quarterly revenues per share for CRISPR Therapeutics AG and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.16 per share, an increase next quarter of $0.06 per share, an increase this year of $0.22 per share, and an increase next year of $0.93 per share.

* CRISPR Therapeutics AG stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.